Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Mizrahi on Encouraging Trial Findings in mCRC

August 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses encouraging trial findings in metastatic colorectal cancer (mCRC).

Dr. Iveson on the IDEA Collaboration in CRC

August 14th 2019

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Dr. Hochster on the Safety Analysis of TAS-102 in CRC and Gastric/GEJ Cancer

August 8th 2019

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC

August 8th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Messersmith on the Need for Biomarkers to Distinguish Between VEGF Inhibitors in CRC

August 7th 2019

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, and professor of medicine, at the University of Colorado School of Medicine, discusses the need for biomarkers to distinguish between VEGF inhibitors in colorectal cancer (CRC).

Dr. Kasi on the Use of Liquid Biopsies in CRC

August 2nd 2019

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.

Novel Therapies for BRAF+ Colorectal Cancer

July 31st 2019

Treating BRAF+ Colorectal Cancer

July 31st 2019

Targeting BRAF and MEK in Colorectal Cancer

July 31st 2019

BRAF Mutations in Colorectal Cancer

July 31st 2019

Emerging Treatment Strategies for Advanced BRAF+ Melanoma

July 31st 2019

Sequencing Therapy in Metastatic BRAF+ Melanoma

July 31st 2019

Selecting Therapy & Managing Patients With BRAF+ Melanoma

July 31st 2019

Trials and Treatment in Advanced Melanoma

July 31st 2019

Recommendations for Molecular Testing in Melanoma

July 31st 2019

BRAF and MEK in Melanoma

July 31st 2019

Developments in the Management of Stage III Melanoma

July 31st 2019

Unmet Needs in BRAF+ NSCLC

July 31st 2019

Treatment Considerations for BRAF+ NSCLC

July 31st 2019

Molecular Testing in NSCLC

July 31st 2019